Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Withdrawal and reintroduction of pharmacological treatment of epilepsy in paediatric patients. Our experience].

Revista de neurologia·2024
Same author

RETRACTED: "The hippocampus in spontaneously hypertensive rats: a quantitative microanatomical study" [Neurosci. 100(2) (2000) 251-258].

Neuroscience·2024
Same author

Calcitonin levels in autoimmune atrophic gastritis-related hypergastrinemia.

Journal of endocrinological investigation·2023
Same author

The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review.

Autoimmunity reviews·2023
Same author

A case of cerebral salt wasting syndrome in a patient with central diabetes insipidus and status epilepticus.

Journal of endocrinological investigation·2023
Same author

A case report of PTH elevation due to immunoassay interference.

Journal of endocrinological investigation·2022

Related Experiment Video

Updated: May 27, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Aldosterone does not modify gene expression in human endothelial cells.

A Verhovez1, T A Williams, F Morello

  • 1Department of Internal Medicine, University of Torino, Torino, Italy. a.verhovez@gmail.com

Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|November 10, 2011
PubMed
Summary
This summary is machine-generated.

Aldosterone does not affect gene expression in human endothelial cells, as their mineralocorticoid receptors are non-functional. This finding suggests aldosterone has no genomic impact on healthy endothelial cells, challenging previous assumptions about its vascular toxicity.

More Related Videos

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Related Experiment Videos

Last Updated: May 27, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Area of Science:

  • Cardiovascular Biology
  • Endocrinology
  • Molecular Biology

Background:

  • Aldosterone's vascular toxicity is implicated in mineralocorticoid-excess cardiovascular pathology.
  • Endothelial dysfunction is a key feature, but its genomic mechanisms are unclear.

Purpose of the Study:

  • To investigate the genomic molecular mechanisms of aldosterone-induced endothelial dysfunction.
  • To determine if aldosterone impacts gene expression in human endothelial cells via the mineralocorticoid receptor.

Main Methods:

  • Expression microarray analysis of human umbilical vein and coronary artery endothelial cells stimulated with aldosterone.
  • Quantitative reverse transcription PCR (qRT-PCR) for confirmation.
  • Luciferase-reporter assay to assess mineralocorticoid receptor activation.

Main Results:

  • Aldosterone stimulation did not significantly alter gene expression in either endothelial cell type.
  • Microarray and qRT-PCR analyses showed no significant changes.
  • Luciferase assays revealed no mineralocorticoid receptor activation by aldosterone.

Conclusions:

  • Cultured human endothelial cells express non-functional mineralocorticoid receptors.
  • Aldosterone does not modify gene expression in these cells.
  • Evidence suggests aldosterone has neither a beneficial nor harmful genomic effect on healthy endothelial cells.